Ignite Creation Date:
2024-07-17 @ 11:14 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06478355
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-27
First Post:
2024-06-13
Brief Title:
Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell CarcinomaChinECR
Sponsor:
Hebei Medical University Fourth Hospital
Organization:
Hebei Medical University Fourth Hospital
Study Overview
Official Title:
Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinomaa Real-world Study From China
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial aims to assess efficacy and safety of immunotherapy combined with chemoradiotherapy for first-line treatment of esophageal squamous cell carcinoma
Detailed Description:
Esophageal squamous cell carcinoma is a highly aggressive malignancy with squamous cell carcinoma accounting for over 90 of esophageal cancer cases in China According to the American Cancer Society the 5-year survival rates vary among patients at different stages of esophageal cancer approximately 50 for early and mid-stage cases around 26 for locally advanced cases and only 5 for those with distant metastasisIn recent years immunotherapy combined with chemotherapy has emerged as the first-line standard treatment for advanced esophageal cancer and several phase III trials of immunotherapy combined with radiotherapy are currently underway for locally advanced esophageal cancer Despite being a novel treatment strategy for patients with locally advanced esophageal cancer there remains a lack of sufficient evidence-based medical data supporting the use of immunotherapy combined with chemoradiotherapyIn recent years immunotherapy combined with chemotherapy has emerged as the first-line standard treatment for advanced esophageal cancer and several phase III trials of immunotherapy combined with radiotherapy are currently underway for locally advanced esophageal cancer Despite being a novel treatment strategy for patients with locally advanced esophageal cancer there remains a lack of sufficient evidence-based medical data supporting the use of immunotherapy combined with chemoradiotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None